A central nervous system (CNS) tumor begins when healthy cells in the brain or the spinal cord change and grow out of control, forming a mass, or tumor. If the tumor is malignant, it can spread to other parts of the body or brain, effecting a child’s thought processes and movements.
Our neuro-oncology team leads many different CNS tumor trials in coordination with sites around the world testing combinations of existing treatments, new approaches to radiation therapy or surgery, and new ways to relieve symptoms and side effects during treatment.
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I- omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases.
Protocol ID: Y-mAbs 101 Disease: NBL Who can participate?: Patients must be b/t the ages of birth and 18 yr at the time of screening. Life expectancy of at least 3 months. Must have a histologically confirmed dx of NB w/ relapse in the CNS or LM. Must have stable systemic disease not requiring chemo/ immunotherapy as judged by the investigator. Lead Researcher: Keri A. Streby
A Phase 1 Open Label, Multi Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Protocol ID: BXQ-350.AD Diseases: Diffuse Midline Glioma and Diffuse intrinsic pontine glioma (DIPG) Who Can Participate?: New diagnosis, ages 1 to 30 Lead Researcher: Maryam Fouladi, MD
A Phase 1b Study of PTC596 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Protocol ID: CONNECT1702 Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 1 to 21 Lead Researcher: Maryam Foudladi, MD
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Protocol ID: ANBL1821 Disease: NBL Who can participate?: Patients ≥ 1 year of age at the time of enrollment are eligible for this study. Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines at the time of initial diagnosis. Patients must have ONE of the following:
First episode of recurrent disease following completion of aggressive multi-drug frontline therapy. First episode of progressive disease during aggressive multi-drug frontline therapy. Primary resistant/refractory disease
Lead Researcher: Mark A. Ranalli
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Protocol ID: ACNS1723 Diseases: CNS Tumors High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 3 to 21 Lead Researcher: Mark A. Ranalli, MD
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations
Protocol ID: ACNS1721 Disease: CNS Who can participate?: Stratum 2 (IDH mutant): Patients must be ≥ 3 years of age and ≤ 25 years of age at the time of enrollment. Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1 (see Section 3.1): Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma, Negative results for H3 K27M by immunohistochemistry (IHC), Negative results for BRAFV600 mutation by Next-Generation Sequencing (NGS)." Lead Researcher: Mark A. Ranalli
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Protocol ID: ACNS1833 Diseases: CNS Tumors and Low Grade Glioma (LGG) Who Can Participate?: Ages 2 to 21
Lead Researcher: Mark A. Ranalli, MD
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Protocol ID: ACNS1831 Diseases: CNS Tumors, Low Grade Glioma (LGG), and Neurofibromatosis Who Can Participate?: New diagnosis, ages 2 to 21 Lead Researcher: Mark A. Ranalli, MD
A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma with Dinutuximab +/- Lenalidomide
Protocol ID: NANT 2013-01 Disease: NBL Who can participate?: Must be ≤ 30 yrs of age. Diagnosis of HR neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. Recurrent/progressive, refractory or persistent disease based upon the response to prior therapy according to the protocol’s guidelines. Lead Researcher: Keri A. Streby
A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High-Grade Glioma (Excluding Diffuse Instrinsic Pontine Glioma)
Protocol ID: PNOC008 Disease: High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 0 to 21 Lead Researcher: Diana S. Osorio, MD
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or CNS Tumors and a Safety and Efficacy Trial of REGN2810 in Combiantion with Radiotherapy in Pediatric Patients with ndDIPG, ndHGG and rHGG
Protocol ID: PNOC013 Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG) Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 25 Lead Researcher: Diana S. Osorio, MD
A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent HGG
Protocol ID: c cc Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Medulloblastoma Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 39 Lead Researcher: Diana S. Osorio, MD
HEAD START 4 PROTOCOL: Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma And Other Central Nervous System Embryonal Tumors. Clinical And Molecular Risk-Tailored Intensive And Compressed Induction Chemotherapy Followed By Consolidation With Randomization To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
Protocol ID: Head Start 4 Diseases: CNS Tumors and Medulloblastoma Who Can Participate?: New diagnosis, ages 0 to 9 Lead Researcher: Randal S. Olshefski, MD
MIBG or Crizotinib add to Intensive Therapy for children with newly diagnosed with high risk neuroblastoma
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Enrollment ANBL00B1 or APEC14B1; less than 30; dx NBL high risk with no prior systemic therapy.
Lead Researcher: Mark A. Ranalli
NCH Protocol PBTB: Pediatric Brain Tumor Bank
Protocol ID: PBTB Diseases: CNS Tumors Who Can Participate?: Ages 0 to 21 Lead Researcher: Diana S. Osorio, MD
Neuroblastoma Biology Studies
Neuroblastoma Classification Biology Studies
Protocol ID: ANBL00B1
Disease: NBL
Who can participate?: All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. Lead Researcher: Mark A. Ranalli
PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONS
Protocol ID: APEC1621K Diseases: CNS Tumors, Langerhans cell histiocytosis (LCH), Neuroblastoma (NBL), Non-Hodgkin lymphoma (NHL), and Sarcoma Who Can Participate?: Replapse/Refractory, age 1 to 21 Lead Researcher: Mark A. Ranalli, MD
PHASE 2 SUBPROTOCOL OF TIPIFARNIB IN PATIENTS WITH TUMORS HARBORING HRAS GENOMIC ALTERATIONS
Protocol ID: APEC1621M Diseases: CNS Tumors, Carcinoma, Diffuse intrinsic pontine glioma (DIPG), Ewing Sarcoma (EWS), Ganglioneuroblastoma (GBN), Germ cell tumor, High Grade Glioma (HGG), Low Grade Glioma (LGG), Medulloblastoma, Neuroblastoma (NBL), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Osteosarcoma (OS), Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Synovial sarcoma, and Wilms tumor Who Can Participate?: Ages 1 to 21 Lead Researcher: Mark A. Ranalli, MD
PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent ATRT
Protocol ID: PNOC005 Diseases: Atypical Teratoid Rhabdoid Tumor, CNS Tumors, and Medulloblastoma Who Can Participate?: Replase/Refractory, ages 1 to 39 Lead Researcher: Diana S. Osorio, MD
PNOC 007, H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC for the Treatment of newly diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as other newly diagnosed HLA-A2+ H3.3K27M Positive Gliomas
Protocol ID: PNOC007 Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Low Grade Glioma (LGG) Who Can Participate?: New diagnosis, ages 3 to 21 Lead Researcher: Diana S. Osorio, MD
Study of 12Il-Metaiodabenzylguanidine (131i-MIBG) or Crizotinib added to intensive therapy for children with newly diagnosed HR NBL
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Must be enrolled on ANBL00B1 or APEC14B1; new diagnosed NBL or ganglioneuroblastoma; >1 y <30y age.
Lead Researcher: Mark A. Ranalli
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma *Patient must be enrolled on ANBL00B1 prior to enrollment
Protocol ID: ANBL1232
Disease: NBL
Who can participate?: < 12 months of age at diagnosis with INRG Stage L1 or < 18 months of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma.
Lead Researcher: Mark A. Ranalli
Late Effects After High Risk Neuroblastoma Study
Protocol ID: ALTE15N2 Disease: NBL Who can participate?: Study Patients must have been enrolled on COG Neuroblastoma Biology Study ANBL00B1. Patients must be ≥ 5 and ≤ 50 years of age at study enrollment. Patient must have been diagnosed with high-risk neuroblastoma per ANBL00B1 definition. Patient must have been diagnosed on or after January 1, 2000. At least 5 years must have elapsed since diagnosis. Lead Researcher: Mark A. Ranalli, MD
Phase 2 Study of Reduced Therapy for Newly Diagnosed Average Risk WNT-Driven Medulloblastoma Patients
Protocol ID: ACNS1422 Disease: CNS Who can participate?: Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment. Patients must be newly diagnosed and have: Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1 (see Section 3.1): classical histologic type (non LC/A) WNT medulloblastoma, positive nuclear β-catenin by IHC, positive for CTNNB1 mutation, negative for MYC and MYCN by FISH. Lead Researcher: Mark A. Ranalli, MD
A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma
Protocol ID: LGG-1403 Untreated LGG Disease: CNS Who can participate?: Patients must be less than 21 years of age at study entry. Patients who are newly OR previously diagnosed with low grade glioma (LGG), who have not been treated with any modality besides surgery or corticosteroids. Untreated astrocytomas or other eligible tumors interpreted as low grade. Lead Researcher: Diana S. Osorio, MD
A Phase II Study of 131I-Metaiodobenzylguanidine (131I - MIBG) Therapy for Patients with MIBG Avid Tumors
Protocol ID: MIBG Disease: NBL Who can participate?: Patients must be between 12 months and 65 years at the time of study enrollment. Lead Researcher: Mark A. Ranalli, MD
NMTT - Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Protocol ID: NMTRC014
Disease: NBL Who can participate?: ≤ 30.99 years of age and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis. Lead Researcher: Keri A. Streby, MD
A central nervous system (CNS) tumor begins when healthy cells in the brain or the spinal cord change and grow out of control, forming a mass, or tumor. If the tumor is malignant, it can spread to other parts of the body or brain, effecting a child’s thought processes and movements.
Our neuro-oncology team leads many different CNS tumor trials in coordination with sites around the world testing combinations of existing treatments, new approaches to radiation therapy or surgery, and new ways to relieve symptoms and side effects during treatment.
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I- omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases.
Protocol ID: Y-mAbs 101 Disease: NBL Who can participate?: Patients must be b/t the ages of birth and 18 yr at the time of screening. Life expectancy of at least 3 months. Must have a histologically confirmed dx of NB w/ relapse in the CNS or LM. Must have stable systemic disease not requiring chemo/ immunotherapy as judged by the investigator. Lead Researcher: Keri A. Streby
A Phase 1 Open Label, Multi Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Protocol ID: BXQ-350.AD Diseases: Diffuse Midline Glioma and Diffuse intrinsic pontine glioma (DIPG) Who Can Participate?: New diagnosis, ages 1 to 30 Lead Researcher: Maryam Fouladi, MD
A Phase 1b Study of PTC596 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Protocol ID: CONNECT1702 Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 1 to 21 Lead Researcher: Maryam Foudladi, MD
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Protocol ID: ANBL1821 Disease: NBL Who can participate?: Patients ≥ 1 year of age at the time of enrollment are eligible for this study. Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines at the time of initial diagnosis. Patients must have ONE of the following:
First episode of recurrent disease following completion of aggressive multi-drug frontline therapy. First episode of progressive disease during aggressive multi-drug frontline therapy. Primary resistant/refractory disease
Lead Researcher: Mark A. Ranalli
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Protocol ID: ACNS1723 Diseases: CNS Tumors High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 3 to 21 Lead Researcher: Mark A. Ranalli, MD
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations
Protocol ID: ACNS1721 Disease: CNS Who can participate?: Stratum 2 (IDH mutant): Patients must be ≥ 3 years of age and ≤ 25 years of age at the time of enrollment. Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1 (see Section 3.1): Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma, Negative results for H3 K27M by immunohistochemistry (IHC), Negative results for BRAFV600 mutation by Next-Generation Sequencing (NGS)." Lead Researcher: Mark A. Ranalli
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Protocol ID: ACNS1833 Diseases: CNS Tumors and Low Grade Glioma (LGG) Who Can Participate?: Ages 2 to 21
Lead Researcher: Mark A. Ranalli, MD
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Protocol ID: ACNS1831 Diseases: CNS Tumors, Low Grade Glioma (LGG), and Neurofibromatosis Who Can Participate?: New diagnosis, ages 2 to 21 Lead Researcher: Mark A. Ranalli, MD
A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma with Dinutuximab +/- Lenalidomide
Protocol ID: NANT 2013-01 Disease: NBL Who can participate?: Must be ≤ 30 yrs of age. Diagnosis of HR neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. Recurrent/progressive, refractory or persistent disease based upon the response to prior therapy according to the protocol’s guidelines. Lead Researcher: Keri A. Streby
A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High-Grade Glioma (Excluding Diffuse Instrinsic Pontine Glioma)
Protocol ID: PNOC008 Disease: High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 0 to 21 Lead Researcher: Diana S. Osorio, MD
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or CNS Tumors and a Safety and Efficacy Trial of REGN2810 in Combiantion with Radiotherapy in Pediatric Patients with ndDIPG, ndHGG and rHGG
Protocol ID: PNOC013 Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG) Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 25 Lead Researcher: Diana S. Osorio, MD
A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent HGG
Protocol ID: c cc Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Medulloblastoma Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 39 Lead Researcher: Diana S. Osorio, MD
HEAD START 4 PROTOCOL: Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma And Other Central Nervous System Embryonal Tumors. Clinical And Molecular Risk-Tailored Intensive And Compressed Induction Chemotherapy Followed By Consolidation With Randomization To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
Protocol ID: Head Start 4 Diseases: CNS Tumors and Medulloblastoma Who Can Participate?: New diagnosis, ages 0 to 9 Lead Researcher: Randal S. Olshefski, MD
MIBG or Crizotinib add to Intensive Therapy for children with newly diagnosed with high risk neuroblastoma
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Enrollment ANBL00B1 or APEC14B1; less than 30; dx NBL high risk with no prior systemic therapy.
Lead Researcher: Mark A. Ranalli
NCH Protocol PBTB: Pediatric Brain Tumor Bank
Protocol ID: PBTB Diseases: CNS Tumors Who Can Participate?: Ages 0 to 21 Lead Researcher: Diana S. Osorio, MD
Neuroblastoma Biology Studies
Neuroblastoma Classification Biology Studies
Protocol ID: ANBL00B1
Disease: NBL
Who can participate?: All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. Lead Researcher: Mark A. Ranalli
PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONS
Protocol ID: APEC1621K Diseases: CNS Tumors, Langerhans cell histiocytosis (LCH), Neuroblastoma (NBL), Non-Hodgkin lymphoma (NHL), and Sarcoma Who Can Participate?: Replapse/Refractory, age 1 to 21 Lead Researcher: Mark A. Ranalli, MD
PHASE 2 SUBPROTOCOL OF TIPIFARNIB IN PATIENTS WITH TUMORS HARBORING HRAS GENOMIC ALTERATIONS
Protocol ID: APEC1621M Diseases: CNS Tumors, Carcinoma, Diffuse intrinsic pontine glioma (DIPG), Ewing Sarcoma (EWS), Ganglioneuroblastoma (GBN), Germ cell tumor, High Grade Glioma (HGG), Low Grade Glioma (LGG), Medulloblastoma, Neuroblastoma (NBL), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Osteosarcoma (OS), Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Synovial sarcoma, and Wilms tumor Who Can Participate?: Ages 1 to 21 Lead Researcher: Mark A. Ranalli, MD
PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent ATRT
Protocol ID: PNOC005 Diseases: Atypical Teratoid Rhabdoid Tumor, CNS Tumors, and Medulloblastoma Who Can Participate?: Replase/Refractory, ages 1 to 39 Lead Researcher: Diana S. Osorio, MD
PNOC 007, H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC for the Treatment of newly diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as other newly diagnosed HLA-A2+ H3.3K27M Positive Gliomas
Protocol ID: PNOC007 Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Low Grade Glioma (LGG) Who Can Participate?: New diagnosis, ages 3 to 21 Lead Researcher: Diana S. Osorio, MD
Study of 12Il-Metaiodabenzylguanidine (131i-MIBG) or Crizotinib added to intensive therapy for children with newly diagnosed HR NBL
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Must be enrolled on ANBL00B1 or APEC14B1; new diagnosed NBL or ganglioneuroblastoma; >1 y <30y age.
Lead Researcher: Mark A. Ranalli
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma *Patient must be enrolled on ANBL00B1 prior to enrollment
Protocol ID: ANBL1232
Disease: NBL
Who can participate?: < 12 months of age at diagnosis with INRG Stage L1 or < 18 months of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma.
Lead Researcher: Mark A. Ranalli
Late Effects After High Risk Neuroblastoma Study
Protocol ID: ALTE15N2 Disease: NBL Who can participate?: Study Patients must have been enrolled on COG Neuroblastoma Biology Study ANBL00B1. Patients must be ≥ 5 and ≤ 50 years of age at study enrollment. Patient must have been diagnosed with high-risk neuroblastoma per ANBL00B1 definition. Patient must have been diagnosed on or after January 1, 2000. At least 5 years must have elapsed since diagnosis. Lead Researcher: Mark A. Ranalli, MD
Phase 2 Study of Reduced Therapy for Newly Diagnosed Average Risk WNT-Driven Medulloblastoma Patients
Protocol ID: ACNS1422 Disease: CNS Who can participate?: Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment. Patients must be newly diagnosed and have: Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1 (see Section 3.1): classical histologic type (non LC/A) WNT medulloblastoma, positive nuclear β-catenin by IHC, positive for CTNNB1 mutation, negative for MYC and MYCN by FISH. Lead Researcher: Mark A. Ranalli, MD
A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma
Protocol ID: LGG-1403 Untreated LGG Disease: CNS Who can participate?: Patients must be less than 21 years of age at study entry. Patients who are newly OR previously diagnosed with low grade glioma (LGG), who have not been treated with any modality besides surgery or corticosteroids. Untreated astrocytomas or other eligible tumors interpreted as low grade. Lead Researcher: Diana S. Osorio, MD
A Phase II Study of 131I-Metaiodobenzylguanidine (131I - MIBG) Therapy for Patients with MIBG Avid Tumors
Protocol ID: MIBG Disease: NBL Who can participate?: Patients must be between 12 months and 65 years at the time of study enrollment. Lead Researcher: Mark A. Ranalli, MD
NMTT - Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Protocol ID: NMTRC014
Disease: NBL Who can participate?: ≤ 30.99 years of age and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis. Lead Researcher: Keri A. Streby, MD
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I- omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases.
Protocol ID: Y-mAbs 101 Disease: NBL Who can participate?: Patients must be b/t the ages of birth and 18 yr at the time of screening. Life expectancy of at least 3 months. Must have a histologically confirmed dx of NB w/ relapse in the CNS or LM. Must have stable systemic disease not requiring chemo/ immunotherapy as judged by the investigator. Lead Researcher: Keri A. Streby
A Phase 1 Open Label, Multi Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)
Protocol ID: BXQ-350.AD Diseases: Diffuse Midline Glioma and Diffuse intrinsic pontine glioma (DIPG) Who Can Participate?: New diagnosis, ages 1 to 30 Lead Researcher: Maryam Fouladi, MD
A Phase 1b Study of PTC596 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Protocol ID: CONNECT1702 Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 1 to 21 Lead Researcher: Maryam Foudladi, MD
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
Protocol ID: ANBL1821 Disease: NBL Who can participate?: Patients ≥ 1 year of age at the time of enrollment are eligible for this study. Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines at the time of initial diagnosis. Patients must have ONE of the following:
First episode of recurrent disease following completion of aggressive multi-drug frontline therapy. First episode of progressive disease during aggressive multi-drug frontline therapy. Primary resistant/refractory disease
Lead Researcher: Mark A. Ranalli
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Protocol ID: ACNS1723 Diseases: CNS Tumors High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 3 to 21 Lead Researcher: Mark A. Ranalli, MD
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutations
Protocol ID: ACNS1721 Disease: CNS Who can participate?: Stratum 2 (IDH mutant): Patients must be ≥ 3 years of age and ≤ 25 years of age at the time of enrollment. Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1 (see Section 3.1): Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma, Negative results for H3 K27M by immunohistochemistry (IHC), Negative results for BRAFV600 mutation by Next-Generation Sequencing (NGS)." Lead Researcher: Mark A. Ranalli
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Protocol ID: ACNS1833 Diseases: CNS Tumors and Low Grade Glioma (LGG) Who Can Participate?: Ages 2 to 21
Lead Researcher: Mark A. Ranalli, MD
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Protocol ID: ACNS1831 Diseases: CNS Tumors, Low Grade Glioma (LGG), and Neurofibromatosis Who Can Participate?: New diagnosis, ages 2 to 21 Lead Researcher: Mark A. Ranalli, MD
A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma with Dinutuximab +/- Lenalidomide
Protocol ID: NANT 2013-01 Disease: NBL Who can participate?: Must be ≤ 30 yrs of age. Diagnosis of HR neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. Recurrent/progressive, refractory or persistent disease based upon the response to prior therapy according to the protocol’s guidelines. Lead Researcher: Keri A. Streby
A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High-Grade Glioma (Excluding Diffuse Instrinsic Pontine Glioma)
Protocol ID: PNOC008 Disease: High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 0 to 21 Lead Researcher: Diana S. Osorio, MD
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or CNS Tumors and a Safety and Efficacy Trial of REGN2810 in Combiantion with Radiotherapy in Pediatric Patients with ndDIPG, ndHGG and rHGG
Protocol ID: PNOC013 Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG) Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 25 Lead Researcher: Diana S. Osorio, MD
A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent HGG
Protocol ID: c cc Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Medulloblastoma Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 39 Lead Researcher: Diana S. Osorio, MD
HEAD START 4 PROTOCOL: Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma And Other Central Nervous System Embryonal Tumors. Clinical And Molecular Risk-Tailored Intensive And Compressed Induction Chemotherapy Followed By Consolidation With Randomization To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
Protocol ID: Head Start 4 Diseases: CNS Tumors and Medulloblastoma Who Can Participate?: New diagnosis, ages 0 to 9 Lead Researcher: Randal S. Olshefski, MD
MIBG or Crizotinib add to Intensive Therapy for children with newly diagnosed with high risk neuroblastoma
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Enrollment ANBL00B1 or APEC14B1; less than 30; dx NBL high risk with no prior systemic therapy.
Lead Researcher: Mark A. Ranalli
NCH Protocol PBTB: Pediatric Brain Tumor Bank
Protocol ID: PBTB Diseases: CNS Tumors Who Can Participate?: Ages 0 to 21 Lead Researcher: Diana S. Osorio, MD
Neuroblastoma Biology Studies
Neuroblastoma Classification Biology Studies
Protocol ID: ANBL00B1
Disease: NBL
Who can participate?: All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. Lead Researcher: Mark A. Ranalli
PHASE 2 SUBPROTOCOL OF AG-120 (IVOSIDENIB) IN PATIENTS WITH TUMORS HARBORING IDH1 MUTATIONS
Protocol ID: APEC1621K Diseases: CNS Tumors, Langerhans cell histiocytosis (LCH), Neuroblastoma (NBL), Non-Hodgkin lymphoma (NHL), and Sarcoma Who Can Participate?: Replapse/Refractory, age 1 to 21 Lead Researcher: Mark A. Ranalli, MD
PHASE 2 SUBPROTOCOL OF TIPIFARNIB IN PATIENTS WITH TUMORS HARBORING HRAS GENOMIC ALTERATIONS
Protocol ID: APEC1621M Diseases: CNS Tumors, Carcinoma, Diffuse intrinsic pontine glioma (DIPG), Ewing Sarcoma (EWS), Ganglioneuroblastoma (GBN), Germ cell tumor, High Grade Glioma (HGG), Low Grade Glioma (LGG), Medulloblastoma, Neuroblastoma (NBL), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Osteosarcoma (OS), Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Synovial sarcoma, and Wilms tumor Who Can Participate?: Ages 1 to 21 Lead Researcher: Mark A. Ranalli, MD
PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent ATRT
Protocol ID: PNOC005 Diseases: Atypical Teratoid Rhabdoid Tumor, CNS Tumors, and Medulloblastoma Who Can Participate?: Replase/Refractory, ages 1 to 39 Lead Researcher: Diana S. Osorio, MD
PNOC 007, H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC for the Treatment of newly diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as other newly diagnosed HLA-A2+ H3.3K27M Positive Gliomas
Protocol ID: PNOC007 Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Low Grade Glioma (LGG) Who Can Participate?: New diagnosis, ages 3 to 21 Lead Researcher: Diana S. Osorio, MD
Study of 12Il-Metaiodabenzylguanidine (131i-MIBG) or Crizotinib added to intensive therapy for children with newly diagnosed HR NBL
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Must be enrolled on ANBL00B1 or APEC14B1; new diagnosed NBL or ganglioneuroblastoma; >1 y <30y age.
Lead Researcher: Mark A. Ranalli
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma *Patient must be enrolled on ANBL00B1 prior to enrollment
Protocol ID: ANBL1232
Disease: NBL
Who can participate?: < 12 months of age at diagnosis with INRG Stage L1 or < 18 months of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma.
Lead Researcher: Mark A. Ranalli
Late Effects After High Risk Neuroblastoma Study
Protocol ID: ALTE15N2 Disease: NBL Who can participate?: Study Patients must have been enrolled on COG Neuroblastoma Biology Study ANBL00B1. Patients must be ≥ 5 and ≤ 50 years of age at study enrollment. Patient must have been diagnosed with high-risk neuroblastoma per ANBL00B1 definition. Patient must have been diagnosed on or after January 1, 2000. At least 5 years must have elapsed since diagnosis. Lead Researcher: Mark A. Ranalli, MD
Phase 2 Study of Reduced Therapy for Newly Diagnosed Average Risk WNT-Driven Medulloblastoma Patients
Protocol ID: ACNS1422 Disease: CNS Who can participate?: Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment. Patients must be newly diagnosed and have: Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1 (see Section 3.1): classical histologic type (non LC/A) WNT medulloblastoma, positive nuclear β-catenin by IHC, positive for CTNNB1 mutation, negative for MYC and MYCN by FISH. Lead Researcher: Mark A. Ranalli, MD
A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma
Protocol ID: LGG-1403 Untreated LGG Disease: CNS Who can participate?: Patients must be less than 21 years of age at study entry. Patients who are newly OR previously diagnosed with low grade glioma (LGG), who have not been treated with any modality besides surgery or corticosteroids. Untreated astrocytomas or other eligible tumors interpreted as low grade. Lead Researcher: Diana S. Osorio, MD
A Phase II Study of 131I-Metaiodobenzylguanidine (131I - MIBG) Therapy for Patients with MIBG Avid Tumors
Protocol ID: MIBG Disease: NBL Who can participate?: Patients must be between 12 months and 65 years at the time of study enrollment. Lead Researcher: Mark A. Ranalli, MD
NMTT - Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Protocol ID: NMTRC014
Disease: NBL Who can participate?: ≤ 30.99 years of age and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis. Lead Researcher: Keri A. Streby, MD
Protocol ID: Y-mAbs 101 Disease: NBL Who can participate?: Patients must be b/t the ages of birth and 18 yr at the time of screening. Life expectancy of at least 3 months. Must have a histologically confirmed dx of NB w/ relapse in the CNS or LM. Must have stable systemic disease not requiring chemo/ immunotherapy as judged by the investigator. Lead Researcher: Keri A. Streby
Protocol ID: Y-mAbs 101
Disease: NBL
Who can participate?: Patients must be b/t the ages of birth and 18 yr at the time of screening. Life expectancy of at least 3 months. Must have a histologically confirmed dx of NB w/ relapse in the CNS or LM. Must have stable systemic disease not requiring chemo/ immunotherapy as judged by the investigator.
Protocol ID: BXQ-350.AD Diseases: Diffuse Midline Glioma and Diffuse intrinsic pontine glioma (DIPG) Who Can Participate?: New diagnosis, ages 1 to 30 Lead Researcher: Maryam Fouladi, MD
Protocol ID: BXQ-350.AD
Diseases: Diffuse Midline Glioma and Diffuse intrinsic pontine glioma (DIPG)
Who Can Participate?: New diagnosis, ages 1 to 30
Lead Researcher: Maryam Fouladi, MD
Protocol ID: CONNECT1702 Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 1 to 21 Lead Researcher: Maryam Foudladi, MD
Protocol ID: CONNECT1702
Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG)
Who Can Participate?: New diagnosis, ages 1 to 21
Lead Researcher: Maryam Foudladi, MD
Protocol ID: ANBL1821 Disease: NBL Who can participate?: Patients ≥ 1 year of age at the time of enrollment are eligible for this study. Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines at the time of initial diagnosis. Patients must have ONE of the following:
First episode of recurrent disease following completion of aggressive multi-drug frontline therapy. First episode of progressive disease during aggressive multi-drug frontline therapy. Primary resistant/refractory disease
Lead Researcher: Mark A. Ranalli
Protocol ID: ANBL1821
Who can participate?: Patients ≥ 1 year of age at the time of enrollment are eligible for this study. Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines at the time of initial diagnosis. Patients must have ONE of the following:
- First episode of recurrent disease following completion of aggressive multi-drug frontline therapy.
- First episode of progressive disease during aggressive multi-drug frontline therapy.
- Primary resistant/refractory disease
Lead Researcher: Mark A. Ranalli
Protocol ID: ACNS1723 Diseases: CNS Tumors High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 3 to 21 Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ACNS1723
Diseases: CNS Tumors High Grade Glioma (HGG)
Who Can Participate?: New diagnosis, ages 3 to 21
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ACNS1721 Disease: CNS Who can participate?: Stratum 2 (IDH mutant): Patients must be ≥ 3 years of age and ≤ 25 years of age at the time of enrollment. Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1 (see Section 3.1): Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma, Negative results for H3 K27M by immunohistochemistry (IHC), Negative results for BRAFV600 mutation by Next-Generation Sequencing (NGS)." Lead Researcher: Mark A. Ranalli
Protocol ID: ACNS1721
Disease: CNS
Who can participate?: Stratum 2 (IDH mutant): Patients must be ≥ 3 years of age and ≤ 25 years of age at the time of enrollment. Patients must have eligibility confirmed by rapid central pathology and central molecular screening reviews performed on APEC14B1 (see Section 3.1): Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma, Negative results for H3 K27M by immunohistochemistry (IHC), Negative results for BRAFV600 mutation by Next-Generation Sequencing (NGS)."
Protocol ID: ACNS1833 Diseases: CNS Tumors and Low Grade Glioma (LGG) Who Can Participate?: Ages 2 to 21
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ACNS1833
Diseases: CNS Tumors and Low Grade Glioma (LGG)
Who Can Participate?: Ages 2 to 21
Protocol ID: ACNS1831 Diseases: CNS Tumors, Low Grade Glioma (LGG), and Neurofibromatosis Who Can Participate?: New diagnosis, ages 2 to 21 Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ACNS1831
Diseases: CNS Tumors, Low Grade Glioma (LGG), and Neurofibromatosis
Who Can Participate?: New diagnosis, ages 2 to 21
Protocol ID: NANT 2013-01 Disease: NBL Who can participate?: Must be ≤ 30 yrs of age. Diagnosis of HR neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. Recurrent/progressive, refractory or persistent disease based upon the response to prior therapy according to the protocol’s guidelines. Lead Researcher: Keri A. Streby
Protocol ID: NANT 2013-01
Who can participate?: Must be ≤ 30 yrs of age. Diagnosis of HR neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. Recurrent/progressive, refractory or persistent disease based upon the response to prior therapy according to the protocol’s guidelines.
Lead Researcher: Keri A. Streby
Protocol ID: PNOC008 Disease: High Grade Glioma (HGG) Who Can Participate?: New diagnosis, ages 0 to 21 Lead Researcher: Diana S. Osorio, MD
Protocol ID: PNOC008
Disease: High Grade Glioma (HGG)
Who Can Participate?: New diagnosis, ages 0 to 21
Lead Researcher: Diana S. Osorio, MD
Protocol ID: PNOC013 Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG) Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 25 Lead Researcher: Diana S. Osorio, MD
Protocol ID: PNOC013
Diseases: Diffuse intrinsic pontine glioma (DIPG) and High Grade Glioma (HGG)
Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 25
Protocol ID: c cc Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Medulloblastoma Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 39 Lead Researcher: Diana S. Osorio, MD
Protocol ID: c cc
Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Medulloblastoma
Who Can Participate?: New Diagnosis, Relapse/Refractory, ages 3 to 39
Protocol ID: Head Start 4 Diseases: CNS Tumors and Medulloblastoma Who Can Participate?: New diagnosis, ages 0 to 9 Lead Researcher: Randal S. Olshefski, MD
Protocol ID: Head Start 4
Diseases: CNS Tumors and Medulloblastoma
Who Can Participate?: New diagnosis, ages 0 to 9
Lead Researcher: Randal S. Olshefski, MD
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Enrollment ANBL00B1 or APEC14B1; less than 30; dx NBL high risk with no prior systemic therapy.
Lead Researcher: Mark A. Ranalli
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Enrollment ANBL00B1 or APEC14B1; less than 30; dx NBL high risk with no prior systemic therapy.
Lead Researcher: Mark A. Ranalli
Protocol ID: PBTB Diseases: CNS Tumors Who Can Participate?: Ages 0 to 21 Lead Researcher: Diana S. Osorio, MD
Protocol ID: PBTB
Diseases: CNS Tumors
Who Can Participate?: Ages 0 to 21
Protocol ID: ANBL00B1
Disease: NBL
Who can participate?: All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study. Lead Researcher: Mark A. Ranalli
Protocol ID: ANBL00B1
Disease: NBL
Who can participate?: All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at COG institutions are eligible for this study.
Protocol ID: APEC1621K Diseases: CNS Tumors, Langerhans cell histiocytosis (LCH), Neuroblastoma (NBL), Non-Hodgkin lymphoma (NHL), and Sarcoma Who Can Participate?: Replapse/Refractory, age 1 to 21 Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621K
Diseases: CNS Tumors, Langerhans cell histiocytosis (LCH), Neuroblastoma (NBL), Non-Hodgkin lymphoma (NHL), and Sarcoma
Who Can Participate?: Replapse/Refractory, age 1 to 21
Protocol ID: APEC1621M Diseases: CNS Tumors, Carcinoma, Diffuse intrinsic pontine glioma (DIPG), Ewing Sarcoma (EWS), Ganglioneuroblastoma (GBN), Germ cell tumor, High Grade Glioma (HGG), Low Grade Glioma (LGG), Medulloblastoma, Neuroblastoma (NBL), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Osteosarcoma (OS), Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Synovial sarcoma, and Wilms tumor Who Can Participate?: Ages 1 to 21 Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC1621M
Diseases: CNS Tumors, Carcinoma, Diffuse intrinsic pontine glioma (DIPG), Ewing Sarcoma (EWS), Ganglioneuroblastoma (GBN), Germ cell tumor, High Grade Glioma (HGG), Low Grade Glioma (LGG), Medulloblastoma, Neuroblastoma (NBL), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Osteosarcoma (OS), Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Synovial sarcoma, and Wilms tumor
Who Can Participate?: Ages 1 to 21
Protocol ID: PNOC005 Diseases: Atypical Teratoid Rhabdoid Tumor, CNS Tumors, and Medulloblastoma Who Can Participate?: Replase/Refractory, ages 1 to 39 Lead Researcher: Diana S. Osorio, MD
Protocol ID: PNOC005
Diseases: Atypical Teratoid Rhabdoid Tumor, CNS Tumors, and Medulloblastoma
Who Can Participate?: Replase/Refractory, ages 1 to 39
Protocol ID: PNOC007 Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Low Grade Glioma (LGG) Who Can Participate?: New diagnosis, ages 3 to 21 Lead Researcher: Diana S. Osorio, MD
Protocol ID: PNOC007
Diseases: Diffuse intrinsic pontine glioma (DIPG), High Grade Glioma (HGG), and Low Grade Glioma (LGG)
Who Can Participate?: New diagnosis, ages 3 to 21
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Must be enrolled on ANBL00B1 or APEC14B1; new diagnosed NBL or ganglioneuroblastoma; >1 y <30y age.
Lead Researcher: Mark A. Ranalli
Protocol ID: ANBL1531
Disease: NBL
Who can participate?: Must be enrolled on ANBL00B1 or APEC14B1; new diagnosed NBL or ganglioneuroblastoma; >1 y <30y age.
Lead Researcher: Mark A. Ranalli
Protocol ID: ANBL1232
Disease: NBL
Who can participate?: < 12 months of age at diagnosis with INRG Stage L1 or < 18 months of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma.
Lead Researcher: Mark A. Ranalli
Protocol ID: ANBL1232
Disease: NBL
Who can participate?: < 12 months of age at diagnosis with INRG Stage L1 or < 18 months of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma.
Lead Researcher: Mark A. Ranalli
Protocol ID: ALTE15N2 Disease: NBL Who can participate?: Study Patients must have been enrolled on COG Neuroblastoma Biology Study ANBL00B1. Patients must be ≥ 5 and ≤ 50 years of age at study enrollment. Patient must have been diagnosed with high-risk neuroblastoma per ANBL00B1 definition. Patient must have been diagnosed on or after January 1, 2000. At least 5 years must have elapsed since diagnosis. Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ALTE15N2
Who can participate?: Study Patients must have been enrolled on COG Neuroblastoma Biology Study ANBL00B1. Patients must be ≥ 5 and ≤ 50 years of age at study enrollment. Patient must have been diagnosed with high-risk neuroblastoma per ANBL00B1 definition. Patient must have been diagnosed on or after January 1, 2000. At least 5 years must have elapsed since diagnosis.
Protocol ID: ACNS1422 Disease: CNS Who can participate?: Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment. Patients must be newly diagnosed and have: Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1 (see Section 3.1): classical histologic type (non LC/A) WNT medulloblastoma, positive nuclear β-catenin by IHC, positive for CTNNB1 mutation, negative for MYC and MYCN by FISH. Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ACNS1422
Who can participate?: Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment. Patients must be newly diagnosed and have: Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1 (see Section 3.1): classical histologic type (non LC/A) WNT medulloblastoma, positive nuclear β-catenin by IHC, positive for CTNNB1 mutation, negative for MYC and MYCN by FISH.
Protocol ID: LGG-1403 Untreated LGG Disease: CNS Who can participate?: Patients must be less than 21 years of age at study entry. Patients who are newly OR previously diagnosed with low grade glioma (LGG), who have not been treated with any modality besides surgery or corticosteroids. Untreated astrocytomas or other eligible tumors interpreted as low grade. Lead Researcher: Diana S. Osorio, MD
Protocol ID: LGG-1403 Untreated LGG
Who can participate?: Patients must be less than 21 years of age at study entry. Patients who are newly OR previously diagnosed with low grade glioma (LGG), who have not been treated with any modality besides surgery or corticosteroids. Untreated astrocytomas or other eligible tumors interpreted as low grade.
Protocol ID: MIBG Disease: NBL Who can participate?: Patients must be between 12 months and 65 years at the time of study enrollment. Lead Researcher: Mark A. Ranalli, MD
Protocol ID: MIBG
Who can participate?: Patients must be between 12 months and 65 years at the time of study enrollment.
Protocol ID: NMTRC014
Disease: NBL Who can participate?: ≤ 30.99 years of age and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis. Lead Researcher: Keri A. Streby, MD
Protocol ID: NMTRC014
Who can participate?: ≤ 30.99 years of age and classified as high risk by the criteria used by COG or SIOPEN at the time of diagnosis.
Lead Researcher: Keri A. Streby, MD
